

Figure 1: Therapeutic Potential of Drugs that Target Longevity Pathways




Figure 2: Potential timeline for human clinical trials of drugs to treat Diseases of Aging




Figure 3: Cost-benefit analysis of selected future therapies

(Adapted from Goldman et al., 2005 RAND study)

	Annual Treatment Cost (\$ Billions)		Cost Per Additional Life-Year (\$)
	2015	2030	
Anti-aging Compound (healthy)	48.6	72.8	8,790
Cancer Vaccines	0.5	0.8	18,236
Treatment of Acute Stroke	3.1	4.4	21,905
Telomerase Inhibitors	4.4	6.4	61,884
Alzheimer's Prevention	33.6	49.1	80,334
Intraventricular Cardiodefibrillators	14.0	20.7	103,095
Diabetes Prevention	13.7	20.96	147,199
Antiangiogenesis	38.8	51.9	498,809
Left Ventricular Assist Devices	10.2	14.2	511,962
Pacemaker for Atrial Fibrillation	10.4	13.6	1,403,740